Clinical Immunology

Standard Treatments for Infections and Inflammation

At a Glance

Treatment for IRF2BP2-related immunodeficiency combines immunoglobulin replacement and infection prevention to provide antibody protection with separate medicines for gastrointestinal and other inflammation. Stem cell transplant is considered case by case for severe, refractory disease.

Treating IRF2BP2-related immunodeficiency requires a “two-track” approach. Because the condition causes both a weak immune system (antibody deficiency) and an overactive one (inflammation), doctors must treat each problem separately. While there is no single “cure” that changes your genetics, therapies can manage both sides of the disease to protect your long-term health ^[1]^[2]. Treatment relies on standard antibody-deficiency and organ-specific care.

Track 1: Rebuilding Your Shield (Infections)

If indicated by your antibody levels and infection burden, treatment for the antibody deficiency involves Immunoglobulin Replacement Therapy (IRT). This provides you with the antibodies your body cannot make on its own ^[3].

IVIG and SCIG: You can receive these infusions intravenously (IVIG, commonly once a month in a clinic) or subcutaneously (SCIG, commonly once a week at home). Both are effective at preventing infections ^[4]. SCIG commonly causes local reactions at the injection site, even if it causes fewer systemic reactions like headaches ^[5]^[6].
The “Trough” Goal: Your doctor will monitor your trough level—the amount of IgG in your blood just before your next dose. There is no universal IRF2BP2 or CVID trough threshold; the dose is highly individualized according to your infection history, bronchiectasis, body size, and losses ^[7]. Do not change your dose based on a single number.
Prophylactic Antibiotics: In some cases, especially if you have lung scarring (bronchiectasis) or continue to get infections despite infusions, your doctor may prescribe a daily “preventative” antibiotic ^[8]^[9].

Crucial Note: Immunoglobulin replacement is excellent at preventing pneumonia and sinus infections, but it typically does not fix the inflammatory or GI symptoms ^[10]^[11].

Track 2: Calming the Fire (Inflammation and GI Issues)

The GI issues (like colitis) and inflammatory symptoms associated with the IRF2BP2 gene are treated with immunosuppressants or biologics, depending on the affected organ and severity ^[12].

Standard Medications: Doctors often use corticosteroids or medications like azathioprine for inflammatory bowel issues ^[12]^[13].
Targeted Biologics: Because the IRF2BP2 mutation involves TNF-alpha, medications known as TNF-inhibitors (like infliximab) are sometimes considered based on case-level or extrapolated evidence. However, anti-TNF use in a patient with an inborn error of immunity can increase the risk of serious, opportunistic, and reactivated infections ^[12]^[14].
Safety First: Before starting these immunosuppressants, your clinician must conduct rigorous screening and prevention for tuberculosis, hepatitis, parasites, and review your vaccinations ^[10]^[15].

Advanced and Experimental Options

Hematopoietic Stem Cell Transplant (HSCT): There are no well-established gene-specific HSCT criteria for this condition. Referral to an expert in inborn errors of immunity is appropriate when disease is severe, progressive, or refractory, with a case-by-case risk-benefit discussion. Transplant carries additional risks such as infertility, organ toxicity, and graft-versus-host disease (GvHD), and is not a routine treatment for antibody deficiency alone ^[16]^[17].
The Importance of a Specialized Team: Because this gene is so rare, your treatment plan should be a collaboration between an immunologist, a gastroenterologist, and geneticist to ensure the “two tracks” of your care are always in balance ^[18]^[10].

Patient Action Plan

Work with your clinicians to build an individualized prevention plan, including:

Vaccinations: Discuss which vaccines are safe (avoiding live vaccines) and how immunoglobulin affects your responses.
Early Infection Contact: Create a plan for who to call for fever or respiratory symptoms to start antibiotics promptly.
Airway Clearance: If you have bronchiectasis, plan for airway-clearance support and sputum cultures when sick.

Common questions in this guide

How is IRF2BP2-related immunodeficiency treated?

Treatment uses two tracks. Immunoglobulin replacement and, when needed, preventive antibiotics help reduce infections, while separate medicines are used to control gastrointestinal and other inflammation. A specialist team individualizes the plan.

What is the difference between IVIG and SCIG for IRF2BP2 deficiency?

IVIG gives antibodies through a vein, often about once a month in a clinic. SCIG gives them under the skin, often weekly at home; both can help prevent infections. SCIG may cause more local injection-site reactions but fewer whole-body effects such as headaches.

Does immunoglobulin replacement treat colitis or other inflammation?

Usually not. IVIG and SCIG replace missing antibodies and help prevent infections, but they typically do not resolve inflammatory or gastrointestinal symptoms such as colitis. Those symptoms may require separate organ-specific treatment.

How is my immunoglobulin dose or IgG trough level determined?

The IgG trough is the antibody level measured just before the next dose. There is no single target for everyone with IRF2BP2 deficiency; clinicians adjust treatment based on infection history, bronchiectasis, body size, and antibody or protein losses. Do not change the dose based on one result without discussing it with the care team.

Could an anti-TNF drug such as infliximab help my colitis?

Anti-TNF drugs may be considered for inflammation because IRF2BP2 affects an inflammatory TNF pathway, but evidence in this rare condition is limited and based mainly on individual cases or related conditions. These medicines can raise the risk of serious, unusual, or reactivated infections. Doctors should screen for tuberculosis, hepatitis, and parasites and review prevention measures before treatment.

When might a stem cell transplant be considered?

A hematopoietic stem cell transplant is not routine for antibody deficiency alone, and there are no established IRF2BP2-specific criteria. An expert team may discuss it when disease is severe, worsening, or not responding to treatment, weighing risks such as infertility, organ injury, and graft-versus-host disease.

Should I take preventive antibiotics if I keep getting infections?

Preventive antibiotics may be considered when infections continue despite antibody replacement or when bronchiectasis is present. Your immunologist should weigh your infection history, lung health, and other risks before prescribing and monitoring them.

Get notified when new evidence is published on Common variable immunodeficiency phenotype due to IRF2BP2 deficiency.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References (18)

1
IRF2BP2 deficiency: An important form of common variable immunodeficiency with inflammation.
Udemgba C, Pillay B, Shafer S, et al.
The Journal of allergy and clinical immunology 2025; (155(6)):2052-2062.e5 doi:10.1016/j.jaci.2025.02.038.
PMID: 40090425
2
Novel frameshift variants expand the map of the genetic defects in IRF2BP2.
García-Aznar JM, Maneiro Pampín E, García Ramos M, et al.
Frontiers in immunology 2023; (14()):1279171 doi:10.3389/fimmu.2023.1279171.
PMID: 37876937
3
What Is the Burden of Immunoglobulin Replacement Therapy in Adult Patients With Primary Immunodeficiencies? A Systematic Review.
Jones GL, Vogt KS, Chambers D, et al.
Frontiers in immunology 2018; (9()):1308 doi:10.3389/fimmu.2018.01308.
PMID: 30034388
4
Real-world patterns of immunoglobulin replacement therapy for infection prevention in common variable immunodeficiency: a multicenter nationwide study.
Moral Moral P, Garcia-Bustos V, Balastegui-Martin H, et al.
Frontiers in immunology 2025; (16()):1640290 doi:10.3389/fimmu.2025.1640290.
PMID: 40771807
5
A case report of pregnancy in a patient with common variable immunodeficiency emphasizing the need for personalized immunoglobulin replacement.
Więsik-Szewczyk E, Jahnz-Różyk K
Medicine 2018; (97(44)):e12804 doi:10.1097/MD.0000000000012804.
PMID: 30383634
6
Fatigue and the wear-off effect in adult patients with common variable immunodeficiency.
Hajjar J, Kutac C, Rider NL, et al.
Clinical and experimental immunology 2018; (194(3)):327-338 doi:10.1111/cei.13210.
PMID: 30168848
7
Immunoglobulin G Trough Levels and Infection Risk in Adults with Inborn Errors of Immunity Receiving Immunoglobulin Therapy.
Aktaş ÖÖ, Özer NO, Kaplankıran C, et al.
Medicina (Kaunas, Lithuania) 2025; (61(9)) doi:10.3390/medicina61091549.
PMID: 41010940
8
An IRF2BP2 Variant in a Pediatric Patient with Common Variable Immunodeficiency.
Tekcan D, Ceylan A, Kulhas Celik I, Artac H
Pediatric allergy, immunology, and pulmonology 2025; (38(3)):100-104 doi:10.1177/2151321X251360561.
PMID: 40689779
9
Prescribing Immunoglobulin Replacement Therapy for Patients with Non-classical and Secondary Antibody Deficiency: an Analysis of the Practice of Clinical Immunologists in the UK and Republic of Ireland.
Edgar JDM, Richter AG, Huissoon AP, et al.
Journal of clinical immunology 2018; (38(2)):204-213 doi:10.1007/s10875-017-0469-4.
PMID: 29423883
10
Endoscopic and histopathological hints on infections in patients of common variable immunodeficiency disorder with gastrointestinal symptoms.
Chen Y, You Y, Li J, et al.
BMC gastroenterology 2023; (23(1)):413 doi:10.1186/s12876-023-03052-3.
PMID: 38017379
11
Enteropathy in Common Variable Immunodeficiency.
Grammatikos A
The journal of allergy and clinical immunology. In practice 2026; (14(7)):1540-1545 doi:10.1016/j.jaip.2026.03.021.
PMID: 41935739
12
CVID Enteropathy Is Difficult To Treat and Shows a Heterogeneous Histopathology.
Juliana NM, Severs M, Marsden JW, et al.
Journal of clinical immunology 2025; (45(1)):129.
PMID: 41026260
13
A patient with CVID-enteropathy successfully treated with ustekinumab.
Marley F, Lockett M, Gompels M, Grammatikos A
Immunologic research 2024; (73(1)):19 doi:10.1007/s12026-024-09559-5.
PMID: 39694957
14
Common Variable Immunodeficiency-Associated Inflammatory Enteropathy: The New Era of Biological Therapy.
Arieira C, Dias de Castro F, Moreira MJ, Cotter J
GE Portuguese journal of gastroenterology 2018; (25(6)):322-326 doi:10.1159/000486448.
PMID: 30480050
15
Vedolizumab treatment in adults with immunodeficiency-associated enteropathy: a case series.
Angarola E, Etchevers MJ, De Paula JA, et al.
Frontiers in immunology 2026; (17()):1953966 doi:10.3389/fimmu.2026.1953966.
PMID: 42898158
16
Hematopoietic Stem Cell Transplantation for Primary Immunodeficiency Disorders: Experience from a Referral Center in India.
Uppuluri R, Jayaraman D, Sivasankaran M, et al.
Indian pediatrics 2018; (55(8)):661-664.
PMID: 30218511
17
The Presentation, Diagnosis, and Management of Autosomal Dominant Common Variable Immunodeficiency Type XII with NFKB1 Mutation and Autoimmune Neutropenia Treated with Allogenic Stem Cell Transplantation.
Gold M, Kannan C, Schofield A, et al.
Hematology reports 2025; (17(5)) doi:10.3390/hematolrep17050049.
PMID: 41148944
18
Defining Common Variable Immunodeficiency Disorders in 2020.
Ameratunga R, Allan C, Woon ST
Immunology and allergy clinics of North America 2020; (40(3)):403-420 doi:10.1016/j.iac.2020.03.001.
PMID: 32654689

This page is for informational purposes only and does not constitute medical advice. Your immunologist and other specialists should tailor antibody replacement, infection prevention, and inflammation treatment to your needs.